$INSP
Inspire Medical Systems, Inc. Stock $insp

$insp Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000160955024000044 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$203.2M	$195.9M
YoY Change	32.54%	29.65%
Cost Of Revenue	$32.40M	$29.84M
YoY Change	32.88%	23.05%
Gross Profit	$170.8M	$166.0M
YoY Change	32.48%	30.91%
Gross Profit Margin	84.06%	84.77%
Selling, General & Admin	$130.4M	$132.1M
YoY Change	15.19%	17.28%
% of Gross Profit	76.35%	79.55%
Research & Development	$26.08M	$28.86M
YoY Change	-10.5%	-6.37%
% of Gross Profit	15.27%	17.38%
Depreciation & Amortization	$1.850M	$1.383M
YoY Change	137.18%	109.86%
% of Gross Profit	1.08%	0.83%
Operating Expenses	$156.5M	$160.9M
YoY Change	9.89%	12.2%
Operating Profit	$14.32M	$5.099M
YoY Change	-206.29%	-130.72%
Interest Expense	$5.890M	$5.882M
YoY Change		19.5%
% of Operating Profit	41.14%	115.36%
Other Income/Expense, Net	$6.008M	$5.747M
YoY Change	13.98%	-9521.31%
Pretax Income	$20.33M	$10.85M
YoY Change	-347.88%	-192.4%
Income Tax	$1.800M	$1.100M
% Of Pretax Income	8.86%	10.14%
Net Earnings	$18.50M	$9.793M
YoY Change	-316.59%	-181.94%
Net Earnings / Revenue	9.1%	5.0%
Basic Earnings Per Share	$0.62	$0.33
Diluted Earnings Per Share	$0.60	$0.32
COMMON SHARES
Basic Shares Outstanding	29.82M shares	29.71M shares
Diluted Shares Outstanding	30.63M shares	30.41M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$411.0M	$439.7M
YoY Change	-11.47%	-5.86%
Cash & Equivalents	$147.5M	$188.0M
Short-Term Investments	$263.5M	$251.6M
Other Short-Term Assets	$14.36M	$28.76M
YoY Change	84.08%	231.09%
Inventory	$67.43M	$59.03M
Prepaid Expenses	$14.36M	$28.76M
Receivables	$89.74M	$79.72M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$582.5M	$607.2M
YoY Change	2.27%	8.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$67.45M	$61.70M
YoY Change	109.14%	32.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$113.4M	$26.34M
YoY Change	3680.83%
Other Assets	$10.99M	$11.00M
YoY Change	-5.35%	-5.09%
Total Long-Term Assets	$213.7M	$121.2M
YoY Change	205.67%	108.4%
TOTAL ASSETS
Total Short-Term Assets	$582.5M	$607.2M
Total Long-Term Assets	$213.7M	$121.2M
Total Assets	$796.2M	$728.4M
YoY Change	24.5%	17.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.93M	$33.62M
YoY Change	-12.69%	-15.87%
Accrued Expenses	$39.34M	$32.04M
YoY Change	31.28%	19.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$74.26M	$65.66M
YoY Change	6.1%	-1.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$150.0K	$149.0K
YoY Change	2.74%	-99.33%
Total Long-Term Liabilities	$150.0K	$149.0K
YoY Change	2.74%	-99.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.26M	$65.66M
Total Long-Term Liabilities	$150.0K	$149.0K
Total Liabilities	$99.63M	$90.32M
YoY Change	4.53%	1.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$327.1M	-$345.6M
YoY Change	-9.18%	-1.71%
Common Stock	$30.00K	$30.00K
YoY Change	3.45%	3.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$696.6M	$638.1M
YoY Change
Total Liabilities & Shareholders Equity	$796.2M	$728.4M
YoY Change	24.5%	17.82%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$18.50M	$9.793M
YoY Change	-316.59%	-181.94%
Depreciation, Depletion And Amortization	$1.850M	$1.383M
YoY Change	137.18%	109.86%
Cash From Operating Activities	$52.28M	-$78.00K
YoY Change	1336.35%	-101.53%
INVESTING ACTIVITIES
Capital Expenditures	$8.007M	$12.39M
YoY Change	14.55%	155.26%
Acquisitions
YoY Change
Other Investing Activities	-$94.96M	$18.01M
YoY Change	-30.81%	84.75%
Cash From Investing Activities	-$103.0M	$5.620M
YoY Change	-28.61%	14.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.890M	7.087M
YoY Change	182.57%	-52.54%
NET CHANGE
Cash From Operating Activities	52.28M	-78.00K
Cash From Investing Activities	-103.0M	5.620M
Cash From Financing Activities	9.890M	7.087M
Net Change In Cash	-40.79M	12.63M
YoY Change	-70.24%	-49.32%
FREE CASH FLOW
Cash From Operating Activities	$52.28M	-$78.00K
Capital Expenditures	$8.007M	$12.39M
Free Cash Flow	$44.28M	-$12.47M
YoY Change	-1421.67%	-5362.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2792000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	21567000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	71000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11952000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2222000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3868000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2678000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized After Tax ForeignCurrencyTransactionGainLossRealizedAfterTax	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1100000	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	920000	usd
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29805301	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29805301	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29560464	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29560464	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	496008000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7377000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1746000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	90000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18225000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	118000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15424000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	529359000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27376000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1252000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4907000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	477000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	593000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	58644000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	39792000	usd
	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	186000	usd
	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	181000	usd
	insp	Accounts Receivable Credit Loss Expense Reversal Write Offs Recoveries Net AccountsReceivableCreditLossExpenseReversalWriteOffsRecoveriesNet	-1133000	usd
	insp	Accounts Receivable Credit Loss Expense Reversal Write Offs Recoveries Net AccountsReceivableCreditLossExpenseReversalWriteOffsRecoveriesNet	881000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-11247000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3116000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25139000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8954000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	18917000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3791000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5004000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11782000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8682000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7495000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8782000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3748000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24089000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8608000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	112035000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	122209000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	10000000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	250000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13915000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1142000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9134000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20490000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4710000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2717000	usd
	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	3431000	usd
	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	2792000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7855000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20565000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-224000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2498000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25459000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	185537000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441592000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188035000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	467051000	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized After Tax ForeignCurrencyTransactionGainLossRealizedAfterTax	-100000	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized After Tax ForeignCurrencyTransactionGainLossRealizedAfterTax	100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized After Tax ForeignCurrencyTransactionGainLossRealizedAfterTax	200000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	100000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	200000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	251683000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	251629000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	26463000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	26344000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	274294000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	274838000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	9117000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	9143000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-200000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	600000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q4	insp	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughYearThree	0	usd
CY2024Q2	insp	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughYearThree	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent recorded on the consolidated balance sheets. However, as of June 30, 2024 and December 31, 2023, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically not been significant.</span></div>
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	256000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1648000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36000	usd
CY2024Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-19000	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-7000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	57000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-7000	usd
CY2024Q2	insp	Accounts Receivable Allowance For Credit Loss Write Off Net Of Recovery AccountsReceivableAllowanceForCreditLossWriteOffNetOfRecovery	-278000	usd
CY2023Q2	insp	Accounts Receivable Allowance For Credit Loss Write Off Net Of Recovery AccountsReceivableAllowanceForCreditLossWriteOffNetOfRecovery	-888000	usd
	insp	Accounts Receivable Allowance For Credit Loss Write Off Net Of Recovery AccountsReceivableAllowanceForCreditLossWriteOffNetOfRecovery	1190000	usd
	insp	Accounts Receivable Allowance For Credit Loss Write Off Net Of Recovery AccountsReceivableAllowanceForCreditLossWriteOffNetOfRecovery	-888000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	515000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	917000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	515000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	917000	usd
CY2024Q2	insp	Number Of Healthcare Systems NumberOfHealthcareSystems	3	healthcaresystem
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10804000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6115000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	48221000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	27770000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	59025000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	33885000	usd
CY2024Q2	insp	Inventory Pre Launch Research And Development InventoryPreLaunchResearchAndDevelopment	6500000	usd
CY2023Q4	insp	Inventory Pre Launch Research And Development InventoryPreLaunchResearchAndDevelopment	900000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1500000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2400000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	71194000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47255000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9493000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7271000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	61701000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39984000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1400000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	700000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2200000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000	usd
CY2024Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	10400000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	10400000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	26635000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	33875000	usd
CY2024Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1431000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1100000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3970000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4291000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32036000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39266000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1388000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	741000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	263000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	151000	usd
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	798000	usd
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	283000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	220000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	132000	usd
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	467000	usd
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	443000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1431000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	760000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1431000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	760000	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	23200000	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	25300000	usd
	us-gaap	Advertising Expense AdvertisingExpense	48800000	usd
	us-gaap	Advertising Expense AdvertisingExpense	48900000	usd
CY2023Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	106000	sqft
CY2023Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	22000	sqft
CY2023Q3	insp	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	renewal_option
CY2023Q2	insp	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	renewal_option
CY2023Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2024Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	18000	sqft
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22189000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22667000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24512000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24846000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P10Y10M24D
CY2024Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.049
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	900000	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
	insp	Defined Contribution Plan Annual Contribution Per Employee Maximum Eligible For Employer Match Percent DefinedContributionPlanAnnualContributionPerEmployeeMaximumEligibleForEmployerMatchPercent	0.06
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2024Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	usd
CY2023Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	900000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2600000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2447141	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	152.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	160691000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	175108	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	195.77
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	176638	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	53.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	24139000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	43241	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	226.85
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2402370	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	161.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	66313000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1645593	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	131.83
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	66291000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	91400000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	13781	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	228.51
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1100000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1700000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	usd
CY2024Q2	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	195885000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	151092000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	359895000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	278989000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	61701000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39984000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3006926	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2904820	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001609550-24-000044-index-headers.html	Edgar Link	pending
0001609550-24-000044-index.html	Edgar Link	pending
0001609550-24-000044.txt	Edgar Link	pending
0001609550-24-000044-xbrl.zip	Edgar Link	pending
a2024-q2ex31x1.htm	Edgar Link	pending
a2024-q2ex31x2.htm	Edgar Link	pending
a2024-q2ex32x1.htm	Edgar Link	pending
a2024-q2ex32x2.htm	Edgar Link	pending
employmentagreement_meli.htm	Edgar Link	pending
employmentagreement_meli001.jpg	Edgar Link	pending
employmentagreement_meli002.jpg	Edgar Link	pending
employmentagreement_meli003.jpg	Edgar Link	pending
employmentagreement_meli004.jpg	Edgar Link	pending
employmentagreement_meli005.jpg	Edgar Link	pending
employmentagreement_meli006.jpg	Edgar Link	pending
employmentagreement_meli007.jpg	Edgar Link	pending
employmentagreement_meli008.jpg	Edgar Link	pending
employmentagreement_meli009.jpg	Edgar Link	pending
employmentagreement_meli010.jpg	Edgar Link	pending
employmentagreement_meli011.jpg	Edgar Link	pending
employmentagreement_meli012.jpg	Edgar Link	pending
employmentagreement_meli013.jpg	Edgar Link	pending
employmentagreement_meli014.jpg	Edgar Link	pending
employmentagreement_meli015.jpg	Edgar Link	pending
employmentagreement_meli016.jpg	Edgar Link	pending
employmentagreement_meli017.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
insp-20240630.htm	Edgar Link	pending
insp-20240630.xsd	Edgar Link	pending
insp-20240630_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
insp-20240630_cal.xml	Edgar Link	unprocessable
insp-20240630_def.xml	Edgar Link	unprocessable
insp-20240630_lab.xml	Edgar Link	unprocessable
insp-20240630_pre.xml	Edgar Link	unprocessable
insp-20240630_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSP
Inspire Medical Systems, Inc. Stock $insp

2024 Q3 Form 10-Q Financial Statement

#000160955024000044 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP Inspire Medical Systems, Inc. Stock $insp

2024 Q3 Form 10-Q Financial Statement

#000160955024000044 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP
Inspire Medical Systems, Inc. Stock $insp